Krishna Institute of Medical Sciences (KIMS) Q4 24/25 earnings summary

Executive summary

• FY25 saw strong growth with total revenue reaching INR 30,670 Mn, up 22% year-over-year, and EBITDA at INR 8,148 Mn, up 24.7% year-over-year; PAT for FY25 was INR 4,148 Mn, up 23.5% year-over-year.

• Q4 FY25 revenue was INR 801 crore, up 25.7% year-over-year, with EBITDA at INR 203 crore, up 24.4% year-over-year, and PAT at INR 106 crore, up from INR 72 crore in Q4 FY24.

• The group completed the acquisition of Queen's NRI Hospital, making it a wholly owned subsidiary.

• Expansion included new hospitals in Nashik, Sangli, Kannur, Kollam, Guntur, Vizag, and a soft launch in Thane, with further launches planned in Bangalore and Mumbai.

• Technological advancements included South India's first Gamma Knife, MRI-guided focused ultrasound, and TULSA-PRO for prostate care.

Financial highlights

• FY25 consolidated revenue from operations was INR 30,351 Mn, up from INR 24,982 Mn year-over-year; consolidated EBITDA at INR 8,148 Mn, up 24.7% year-over-year.

• Q4 consolidated revenue was INR 801 crore, up 25.7% year-over-year; Q4 EBITDA at INR 203 crore, up 24.4% year-over-year.

• Consolidated EPS for FY25 was INR 9.6, up 24.7% year-over-year.

• PAT for FY25 was INR 4,148 Mn, up 23.5% year-over-year.

• Q4 FY25 EBITDA margin at 25.3%, PAT margin at 13.2%, and EPS at INR 2.5, up 55.5% year-over-year.

Outlook and guidance

• Telangana cluster expected to sustain and expand margins, driven by new doctor onboarding and specialty growth.

• New units in Thane and Bangalore to be EBITDA neutral or positive within 12 months of commissioning, though initial drag expected in FY26.

• Expansion plans include new hospitals in Bangalore, Mumbai, Srikakulam, Ongole, Anantapur, Kondapur, and Rajahmundry, with significant capex and incremental bed additions expected from FY26 onwards.

• ARPOB growth in Telangana and Andhra projected at 15-20% annually, with group ARPOB expected to trend towards INR 50,000-55,000 in 2-3 years.

• 20% revenue CAGR over five years considered achievable with bed and ARPOB growth.